Human pluripotent stem cell single cell line establishment method

By using culture medium with specific ingredients and multi-stage differentiation inducers, the problem of single-cell system building of pluripotent stem cells under serum-free and feeder-free conditions was solved, the survival rate and dry stability were improved, and efficient islets were achieved β-cell differentiation.

CN118979011APending Publication Date: 2024-11-19HANGZHOU RUIPU CHENCHUANG TECH CO LTD
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
CN202411473228.2
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-10-22
Publication Date
2024-11-19

AI Technical Summary

Technical Problem

The existing technology is difficult to effectively carry out single-cell system construction of human pluripotent stem cells under serum-free and feeder-free conditions, resulting in low single-cell survival rate, loss of stemness and genetic stability problems, and abnormalities in single-cell system construction. Karyotype risk.

Method used

Using specific ingredient-specific system culture medium and single-cell growth medium, including ROCK inhibitors, MEK inhibitors, GSK3 inhibitors, CloneR2, human modulin and antioxidants, performed by limited dilution method and multi-stage differentiation inducer compositions Monoclonal system of pluripotent stem cells and islet β-cell differentiation.

Benefits of technology

It improves single-cell survival rate and monoclonal formation efficiency, ensures dry stability and genetic stability, and successfully achieves efficient differentiation of pancreatic β cells.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118979011A_ABST
    Figure CN118979011A_ABST
Patent Text Reader

Abstract

The invention relates to a method suitable for pluripotent stem cell (PSC) single cell line establishment, the method is characterized in that a line establishment culture medium, a single cell acquisition mode and a single cell growth culture medium are used, the line establishment culture medium comprises a ROCK inhibitor, a MEK inhibitor and a GSK3 inhibitor, the single cell acquisition mode is a limited dilution method, and the single cell growth culture medium is a single cell growth medium. The single cell growth culture medium contains CloneR2. The invention also relates to a culture medium used by the method, and the culture medium has advantages in maintaining the dryness of the pluripotent stem cell single cell and promoting the proliferation of the pluripotent stem cell single cell.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present application relates to the field of biomedicine, and specifically to a method for establishing a human pluripotent stem cell (PSC) line. Background Art

[0002] In recent years, stem cell research has developed into a promising field, promoting the basic transformation and clinical progress of stem cells in the field of regenerative medicine. In particular, pluripotent stem cells (PSCs), such as human embryonic stem cells (hESCs) and human induced pluripotent stem cells (hiPSCs), are of great significance in regenerative medicine and transplantation medicine, disease modeling, drug discovery screening, and human developmental biology. However, there are still many problems to be solved if they are applied to production, and the first is to improve the method of establishing stem cell lines.

[0003] hESCs are the first stem cells to be studied and applied. hESCs are isolated from embryos that have developed to the blastocyst stage. The classic method for establishing embryonic stem cell lines is to first remove the zona pellucida by enzymatic hydrolysis or directly separate the zona pellucida of the blastocyst by mechanical methods, then dissolve the trophoblast using animal serum using immunosurgery methods, and then culture the separated inner cell mass (ICM) on mouse embryonic fibroblasts (MEFs) to finally obtain hESCs. In order to overcome the ethical and immunogenic challenges associated with hESCs, hiPSCs have become a promising alternative. The existing methods for establishing lines are as follows: (1) hiPSC line establishment through retroviral transduction of four or three transcription factors; (2) non-integrating reprogramming methods such as Sendai virus, free plasmids, RNA, and small molecule compounds to create hiPSC cell lines that do not carry exogenous reprogramming factors.

[0004] The establishment of hESC and hiPSC lines is basically based on the culture conditions containing xenogeneic serum. The cell clusters are obtained by mechanical separation and finally inoculated on feeder cells to establish the line. For clinical transformation, the establishment and maintenance of pluripotent stem cells should be carried out under xenogeneic and feeder-free culture conditions as much as possible. More and more studies have begun to explore stable methods for establishing lines under serum-free and feeder-free conditions. On the other hand, according to the guidelines of the International Council for Harmonization of Technical Registration of Pharmaceuticals for Human Use (ICH), production cell lines must be derived from single cells, so single-cell line establishment is also an indispensable link in the development of stem cell lines. However, there are bottlenecks in single-cell line establishment. hiPSC is sensitive to various environmental factors, such as osmotic pressure, pH value, nutrient availability, mechanical stress, etc.; most importantly, in the process of single-cell line establishment, due to the loss of cell-cell and cell-extracellular matrix (ECM) interactions and the combined effects of the above factors, the single-cell survival rate is significantly reduced and the stemness is lost, which greatly increases the difficulty of line establishment. Therefore, it is unclear whether single-cell establishment of hiPSC lines under serum-free and feeder-free conditions can maintain long-term in vitro growth of hiPSCs without changing their characteristics, and whether there is a higher risk of producing abnormal karyotype hiPSCs during long-term culture.

[0005] It can be seen that there is still a need in the art to develop a single-cell method for establishing human pluripotent stem cells under serum-free and feeder-free conditions, and the method needs to be able to meet multiple requirements such as single-cell survival, single-clone origin verification, stemness maintenance, and genetic stability. Summary of the invention

[0006] The inventors of the present invention have found through research that, in the method for establishing a single cell line of human pluripotent stem cells, a culture medium with specific components combined with a specific means of obtaining single cells can obtain a human pluripotent stem cell monoclonal cell line with ideal properties, thereby completing the present invention. On this basis, the inventors also found that the human pluripotent stem cell monoclonal cell line obtained by the method of the present invention is particularly suitable for differentiation of pancreatic β cells, which is reflected in the fact that pancreatic β cells account for the highest proportion of differentiated pancreatic islet cells.

[0007] In a first aspect, the present application provides a method for establishing a monoclonal cell line of a pluripotent stem cell (PSC), the method comprising the use of a line establishment medium and / or a single cell growth medium. The line establishment medium and / or the single cell growth medium plays a role in maintaining stemness and proliferation capacity during the monoclonal line establishment process.

[0008] In a specific embodiment, the method comprises the use of the establishment medium, which comprises a ROCK inhibitor, a MEK inhibitor and a GSK3 inhibitor. In a further embodiment, the method further comprises the use of CloneR2.

[0009] In a specific embodiment, the method further comprises use of the single cell growth medium, wherein the single cell growth medium comprises CloneR2.

[0010] In a specific embodiment, the ROCK inhibitor in the culture medium is Y-27632. In a specific embodiment, the MEK inhibitor is PD0325901. In a specific embodiment, the GSK3 inhibitor is CHIR-99021.

[0011] In a further embodiment, the establishment culture medium further comprises human heregulin, a growth factor and an antioxidant.

[0012] In a specific embodiment, the human heregulin is recombinant human heregulin β1. In a specific embodiment, the growth factor is fibroblast growth factor 2 (FGF2). In a specific embodiment, the antioxidant is sodium vitamin C phosphate.

[0013] In a preferred embodiment, the pluripotent stem cells are induced pluripotent stem cells (iPSCs), more preferably human iPSCs.

[0014] In certain embodiments, the method comprises culturing the pluripotent stem cells in a lineage establishment medium before obtaining a single cell of the pluripotent stem cell. In a preferred embodiment, the contact is for 10-12 days. The pluripotent stem cells treated with the lineage establishment medium have advantages in maintaining stemness and proliferation ability when used for monoclonal sorting.

[0015] In certain embodiments, the method comprises: (1) obtaining a single cell of a pluripotent stem cell from a pluripotent stem cell culture cultured in a lineage establishment medium; (2) culturing the single cell of the pluripotent stem cell obtained in step (1) in a single cell growth medium to form a single clone of the pluripotent stem cell; (3) Cultivating a single clone of the pluripotent stem cells obtained in step (2) in complete culture medium.

[0016] In certain embodiments, in step (1), a single cell of pluripotent stem cells is obtained by limiting dilution. In a preferred embodiment, the pluripotent stem cell culture cultured in the establishment medium is diluted to 2-200 cells / mL, preferably 5-120 cells / mL.

[0017] In a further embodiment, in step (2), the single cell of the selected pluripotent stem cell is cultured in a single cell growth medium for 3-5 days, preferably 4 days.

[0018] In a further embodiment, in step (3), the single clone of the pluripotent stem cell is cultured in the complete medium to the end point of the line establishment.

[0019] In a second aspect, the present application provides the use of a monoclonal cell line of a pluripotent stem cell (PSC) established by the method of the first aspect to prepare downstream cells. In a preferred embodiment, the cells are pancreatic islet cells, preferably pancreatic β cells.

[0020] In certain embodiments, the differentiation method comprises the step of contacting the monoclonal cell line of the pluripotent stem cells with a differentiation inducing agent, which comprises the following six stages: (1) contacting cells with a first-stage differentiation inducing agent composition; (2) contacting the cells with a second stage differentiation inducing agent composition; (3) contacting the cells with a third stage differentiation inducing agent composition; (4) contacting the cells with a fourth stage differentiation inducing agent composition; (5) contacting the cells with a fifth stage differentiation inducing agent composition; and (6) contacting the cells with a sixth stage differentiation inducing agent composition.

[0021] The first stage differentiation inducer composition comprises the following small molecule compounds or is composed of the following small molecule compounds: TGF-β activator, GSK-3α / β inhibitor, PI3K inhibitor, ROCK inhibitor. More specifically, the first stage differentiation inducer composition is composed of the following small molecule compounds: Activin A; CHIR-99021; PI-103; Y-27632. More specifically, the first stage differentiation inducer composition is composed of the following groups of small molecule compounds: (S1D1) Activin A; CHIR-99021; PI-103; Y-27632; (S1D2-D4) Activin A.

[0022] The second stage differentiation inducer composition comprises or consists of the following small molecule compounds: ALK5 inhibitor; Wnt pathway inhibitor; keratinocyte growth factor. More specifically, the second stage differentiation inducer composition consists of the following small molecule compounds: SB431542; WntC59; KGF.

[0023] The third stage differentiation inducer composition comprises or consists of the following small molecule compounds: BMP type I receptor inhibitor; retinoic acid; Smo antagonist; Wnt pathway inhibitor. More specifically, the third stage differentiation inducer composition consists of the following small molecule compounds: LDN-193189; RA; Sant1; WntC59.

[0024] The fourth stage differentiation inducer composition comprises the following small molecule compounds or is composed of the following small molecule compounds: sirtuins inhibitors; growth factors; PKC activators; Smo antagonists; ROCK inhibitors. More specifically, the fourth stage differentiation inducer composition is composed of the following small molecule compounds: nicotinamide; human epidermal growth factor; TPB; Sant1; Y-27632. More specifically, the fourth stage differentiation inducer composition is composed of the following groups of small molecule compounds: (S4D1) Nicotinamide; human epidermal growth factor; TPB; Sant1; Y-27632; (S4D2-D6) Nicotinamide; human epidermal growth factor; TPB; Sant1; The fifth stage differentiation inducer composition comprises the following small molecule compounds or is composed of the following small molecule compounds: BMP signal inhibitor; anticoagulant; thyroid hormone; TGFβR-1 / ALK5 inhibitor; ROCK inhibitor; Wnt pathway inhibitor; γ-secretase inhibitor; multiple signal pathway activator. More specifically, the fifth stage differentiation inducer composition is composed of the following small molecule compounds: LDN-193189; heparin sodium; triiodothyronine; ALK5 inhibitor II; Y-27632; WntC59; XXI; ISX9.

[0025] (S5D1-D3) LDN-193189; heparin sodium; triiodothyronine; ALK5 inhibitor II; Y-27632; WntC59; XXI; ISX9; (S5D4-D6) LDN-193189; heparin sodium; triiodothyronine; ALK5 inhibitor II; Y-27632; WntC59; XXI; The sixth stage differentiation inducer composition comprises or is composed of the following small molecule compounds: TGFβR-1 / ALK5 inhibitor; anticoagulant; thyroid hormone; Axl inhibitor; ROS inhibitor. More specifically, the sixth stage differentiation inducer composition is composed of the following small molecule compounds: ALK5 inhibitor II; heparin sodium; triiodothyronine; R428; acetylcysteine; zinc sulfate.

[0026] In a third aspect, the present application provides a culture medium composition for use in the line establishment method described in the first aspect, comprising a line establishment medium and a single cell growth medium.

[0027] In a specific embodiment, the establishment medium comprises a ROCK inhibitor, a MEK inhibitor and a GSK3 inhibitor.

[0028] In a specific embodiment, the ROCK inhibitor in the culture medium is Y-27632. In a specific embodiment, the MEK inhibitor is PD0325901. In a specific embodiment, the GSK3 inhibitor is CHIR-99021.

[0029] In a specific embodiment, said single cell growth medium comprises CloneR2.

[0030] In a further embodiment, the establishment culture medium further comprises human heregulin, a growth factor and an antioxidant.

[0031] In a specific embodiment, the human heregulin is recombinant human heregulin β1. In a specific embodiment, the growth factor is fibroblast growth factor 2 (FGF2). In a specific embodiment, the antioxidant is sodium vitamin C phosphate.

[0032] By introducing the above-mentioned establishment medium and single cell growth medium into the establishment of monoclonal pluripotent stem cell lines, the monoclonal pluripotent stem cells obtained by the present invention have the following advantages: (1) high single cell survival rate, the efficiency of monoclonal formation is up to 25%, when the inoculation density is 0.5 cells per well, there is only a single clone in the well; (2) the monoclonal pluripotent stem cell has a normal karyotype and has genetic stability; (3) the stemness is stable, and the results of stemness antibody analysis show that the monoclonal human pluripotent stem cell line obtained by single cell selection and establishment has good stemness maintenance ability; (4) it can effectively connect to downstream differentiation, and the differentiation test results prove that the pluripotent stem cell line obtained by this single cell selection and establishment method can effectively connect to pancreatic islet differentiation. The monoclonal establishment method and / or culture medium protected by the present application can effectively overcome the inherent disadvantages of pluripotent stem cells derived from cell clusters (such as not meeting the ICH guidelines), and can also achieve the purpose of obtaining monoclonal pluripotent stem cells suitable for production, providing a seed cell source for further obtaining pluripotent stem cells suitable for production, and laying a foundation for subsequent process development, preclinical and clinical work.

[0033] Those skilled in the art can easily perceive other aspects and advantages of the present application from the detailed description below. In the detailed description below, only exemplary embodiments of the present application are shown and described. As will be appreciated by those skilled in the art, the content of the present application enables those skilled in the art to modify the disclosed specific embodiments without departing from the spirit and scope of the invention to which the present application relates. Accordingly, the description in the drawings and specification of the present application is merely exemplary and not restrictive. BRIEF DESCRIPTION OF THE DRAWINGS

[0034] The specific features of the invention involved in this application are shown in the attached claims. The features and advantages of the invention involved in this application can be better understood by referring to the exemplary embodiments and drawings described in detail below. The drawings are briefly described as follows: Figure 1 Shown is a single cell image on day 0 marked in the method for establishing a monoclonal cell line of iPSCs described in the present application, with a scale bar of 200 μm.

[0035] Figure 2 Shown is a monoclonal image obtained after labeling and tracking in the method for establishing a monoclonal cell line of iPSCs described in the present application, with a scale of 200 μm.

[0036] Figure 3 Shown are the karyotypes of the iPSC monoclonal cell line obtained by the method for establishing the iPSC monoclonal cell line described in the present application and the control group.

[0037] Figure 4-Figure 9 Shown are the results of flow cytometry analysis of the stemness of monoclonal cell lines of iPSCs of the present invention and a control group. Figure 4 Shown are the results of staining with Nanog antibody; Figure 5 Shown are the results of staining with OCT4 antibody; Figure 6 Shown are the results of staining with SOX-2 antibody; Figure 7 Shown are the results of staining with SSEA antibody; Figure 8 Shown are the results of staining with Tra-1-60 antibody; Fig. 9 The results of staining with Tra-1-81 antibody are shown. Among them, blank represents the result of staining with neither primary antibody nor secondary antibody, control represents the result of staining with secondary antibody alone, and experiment represents the result of staining with both primary antibody and secondary antibody. The calculation method of the positive rate of the corresponding antibody is (positive rate experiment-positive rate blank)-(positive rate control-positive rate blank).

[0038] Fig.10 Shown is a comparison of the efficiency of monoclone formation using a single cell growth medium containing CloneR2 protected by the present invention and a single cell growth medium containing Y-27632.

[0039] Fig.11 Shown is the effect of different single cell isolation methods on the efficiency of single clone formation of the present invention.

[0040] Fig.12 Shown is a schematic diagram of the proliferation status of the first batch of iPSCs after culture in culture medium with different components.

[0041] Fig.13 Shown is a statistical graph of the number of clones grown in each well of the first batch of iPSCs after culture in different compositions of line establishment culture medium.

[0042] Figure 14-15 Shown are the results of flow cytometry analysis of the stemness of the first batch of iPSC monoclonal cells after culture in establishment medium with different components. Fig.14 Shown are the results of staining with OCT4 antibody; Fig.15 Shown are the total number of cells per well in different groups counted before flow cytometry.

[0043] Fig.16 Shown is a schematic diagram of the proliferation status of the second batch of iPSCs after culture in culture medium with different components.

[0044] Figure 17-Figure 18 Shown are the results of flow cytometry analysis of the stemness of the second batch of iPSC monoclonal cells after culture in culture medium with different components. Fig.17 Shown are the results of staining with OCT4 antibody; Fig.18 Shown are the total number of cells per well in different groups counted before flow cytometry.

[0045] Fig.19 Shown is the effect of different components of the single cell growth medium on the efficiency of single clone formation of the present invention.

[0046] Figure 20-21 Shown are the results of analyzing differentiation efficiency by flow cytometry after the monoclonal human pluripotent stem cell line of the present invention was used for subsequent pancreatic islet induced differentiation. Fig. 20 Shown are the differentiation efficiencies at the S1 stage of islet differentiation, where SOX17 and FOXA2 represent markers of committed endoderm; Fig.21 The figure shows the differentiation efficiency at the S6 stage of islet differentiation, where ARX and GCG double positivity are markers of islet α cells, SST and HHEX double positivity are markers of islet δ cells, and NKX6.1 and Cpep double positivity are markers of islet β cells.

[0047] Fig. 22 Shown is a text flow chart for the establishment of monoclonal human pluripotent stem cell lines.

[0048] Fig.23 Shown is a pictorial flowchart for establishing monoclonal human pluripotent stem cell lines, with a scale bar of 200 μm.

[0049] The iPSC monoclonal cell lines obtained by the method for establishing iPSC monoclonal cell lines described in the present application are ZF2301-63#-P5 and ZF2301-67#-P5 shown in the figure; the control group is iPSC derived from cell clusters, namely ZF2301-26#-P5 and ZF2301-27#-P5. DETAILED DESCRIPTION

[0050] The following is an explanation of the implementation of the present invention by means of specific embodiments. Those skilled in the art can easily understand other advantages and effects of the present invention from the contents disclosed in this specification.

[0051] Definition of terms Unless otherwise defined herein, the scientific and technical terms used in this application shall have the meanings commonly understood by those of ordinary skill in the art. In addition, unless the context otherwise requires, singular terms shall include the plural, and plural terms shall include the singular. Generally, the cell and tissue culture, molecular biology, immunology, microbiology, genetics, and proteins and nucleic acids described herein are concepts recognized by those skilled in the art.

[0052] In this application, the term "pluripotent stem cells" generally refers to cells with unlimited proliferation ability and multi-germ layer differentiation ability. Unlike the differentiation ability of adult stem cells in a single germ layer, the pluripotent stem cells have the ability to differentiate into ectoderm, mesoderm, and endoderm cells. Specifically, the pluripotent stem cells may include embryonic stem cells (ESCs) and induced pluripotent stem cells (iPSCs), which are highly similar in function and structure, but differ in their sources.

[0053] In the present application, the term "induced pluripotent stem cells" or "iPSCs" refers to pluripotent stem cells obtained by treating non-pluripotent cells such as somatic cells with genetic modification and / or integration-free reprogramming methods and / or small molecule cocktails.

[0054] The term "non-pluripotent cell" refers to a cell that is not normally pluripotent. Non-pluripotent cells include differentiated cells, such as somatic cells (e.g., skin cells, fibroblasts, blood cells, immune cells, urine cells, hormone-secreting cells, adrenal medullary cells, breast cells, central nervous system (CNS) cells, glial cells, peripheral nervous system (PNS) cells, muscle cells, hematopoietic cells, bone cells, liver cells, fat cells, kidney cells, lung cells, chondrocytes, etc.); or partially differentiated cells, such as various types of progenitor cells that are not pluripotent, or specialized stem cells that can differentiate into specific cell types, or adult stem cells that have multiple differentiation potentials but a less broad differentiation spectrum (e.g., mesenchymal stem cells). The definition of non-pluripotent cells has nothing to do with whether the cell has the ability to divide.

[0055] The term "reprogramming" in the context of the present invention refers to the process of converting non-pluripotent cells into pluripotent cells. "Reprogramming" can be accomplished by transducing some transcription factors (e.g., the four Yamanaka factors) into cells, or by treating cells with small molecule compounds, or by treating cells with transcription factors and small molecule compounds simultaneously.

[0056] The term "chemical reprogramming" in the context of the present invention refers to a reprogramming process that uses only chemical molecules to treat cells without resorting to genetic engineering (such as expression or knockdown / knockout of transcription factors).

[0057] Unless otherwise specified, the reprogrammed cells of the present invention are mammalian cells, such as human cells.

[0058] The term "small molecule compound" in the context of the present invention refers to a compound having a molecular weight of less than 2000 Daltons, preferably less than 1000 Daltons.

[0059] In the present application, the term "chemically induced pluripotent stem cells" or "CiPSCs" refers to induced pluripotent stem cells obtained by chemical reprogramming.

[0060] In this application, the term "monoclonal" refers to a cell cluster derived from the division of the same cell. The term "single cell" refers to the starting point of the division of the aforementioned monoclonal clone, and its morphology is a single cell. Specifically, the single cell can be dispersed in a cell fluid with a sufficient dilution multiple, and other cells are present in the cell fluid; or it can exist in a small culture system (such as a well in a 48-well plate, a 96-well plate or a 384-well plate), and no other cells exist in the system.

[0061] In the present application, the terms "line establishment medium" and "single cell growth medium" may refer to the "line establishment medium" and "single cell growth medium" containing specific components used in the method for establishing a monoclonal cell line of pluripotent stem cells protected by the present application, or may refer to a medium with unspecified components used in the line establishment stage and the single cell growth stage of the method. The specific reference of the "line establishment medium" and "single cell growth medium" can be judged by the context. In the present application, the term "limiting dilution method" is a commonly used method for obtaining single cells. It is mainly to obtain a very low concentration of cell fluid by gradient dilution or direct dilution of a high concentration of cell fluid, and to inoculate the very low concentration of cell fluid into the culture fluid to proliferate it to produce a monoclonal cell line.

[0062] In this application, the term "end point of establishment" refers to the end point of monoclonal iPSC culture. Monoclonal iPSC should have a certain scale (e.g., the number of cells should be at least 103 or even higher) and have stable proliferation ability at the end point of culture.

[0063] In this application, the term "complete medium" refers to a medium that does not contain any molecules of additives specifically specified in this application unless otherwise specified. The specifically specified additives refer to the composition components specifically stated in this application, for example, "CloneR2" in "the single cell growth medium includes CloneR2" is a specifically specified additive. Those skilled in the art need to distinguish between the additives generally described in this application (such as B27, non-essential amino acids, etc.) or the specific formulas of the relevant culture media mentioned in the examples of this application.

[0064] In this application, the term "patient" can generally include humans, non-human primates (e.g., monkeys) or other animals, particularly mammals, such as cows, horses, pigs, sheep, goats, dogs, cats or rodents, such as mice and rats. In particularly preferred embodiments, the patient is a human.

[0065] In the present application, the term "and / or" should be understood as any one element or a combination of any several elements used for connection.

[0066] In this application, the term "comprises", "comprising" or "including" generally means including the features explicitly stated, but not excluding other elements.

[0067] In this application, the term "selected from" generally refers to the objects selected and all combinations thereof. For example, "selected from A, B and C" means all combinations including A, B and C, for example, A, B, C, A+B, A+C, B+C, or A+B+C.

[0068] In this application, the term "about" generally refers to a variation within a range of 0.5%-10% above or below a specified value, for example, 0.5%, 1%, 1.5%, 2%, 2.5%, 3%, 3.5%, 4%, 4.5%, 5%, 5.5%, 6%, 6.5%, 7%, 7.5%, 8%, 8.5%, 9%, 9.5%, or 10% above or below a specified value.

[0069] It should be understood by those skilled in the art that, for the convenience of expression, in the context of the present invention, the combination of compounds used as reprogramming or differentiation inducers is referred to as an "inducer composition", but this does not mean that they must be used as a physically indivisible whole, but also covers the situation where they are used separately. In other words, each small molecule compound contained in the inducer composition of the present invention can exist and be used in an independent manner. For example, the small molecule compound as an inducer can be present in a plurality of different compositions, such as in culture media at different stages, and the inducer combination present in each culture medium can overlap. In the method of using the inducer composition, such as in the reprogramming method, each small molecule compound contained in the inducer composition can be used at the same or different time points, and the time each small molecule compound exists in the system can be the same or different. All of the above embodiments are covered within the scope of the present invention.

[0070] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by those of ordinary skill in the art to which the invention belongs. Methods and materials for use in the present invention are described herein; other suitable methods and materials known in the art may also be used. The materials, methods, and examples are illustrative only and not restrictive. All publications, patent applications, patents, sequences, database entries, and other references mentioned herein are incorporated by reference in their entirety. In the event of a conflict, the present specification (including definitions) shall prevail. DETAILED DESCRIPTION OF THE INVENTION Culture medium On the one hand, the present application provides a method for establishing a monoclonal cell line of a pluripotent stem cell (PSC). The method is characterized by the use of a line establishment medium and / or a single cell growth medium. The line establishment medium and / or the single cell growth medium play a role in maintaining stemness and proliferation capacity during the monoclonal line establishment process.

[0072] In certain embodiments, the method may comprise the use of a culture medium, which may comprise a ROCK inhibitor, a MEK inhibitor and a GSK3 inhibitor. In certain embodiments, the method may further comprise the use of CloneR2.

[0073] ROCK inhibitor refers to any substance that inhibits or reduces the function of ROCK (Rho-associated protein kinase) protein or its signaling pathway in cells, such as small molecules, siRNA, miRNA, antisense RNA, etc. ROCK is a serine / threonine kinase that plays an important role in various biological processes of cells, including the reorganization of the cytoskeleton, the maintenance of cell morphology, cell proliferation, migration and apoptosis, etc. The method for inhibiting or reducing the function of ROCK protein can be to downregulate, reduce, eliminate, inhibit or reduce the expression of ROCK gene or downregulate, reduce, eliminate, inhibit or reduce the activation level of ROCK protein, peptide or polypeptide. The exemplary ROCK inhibitor used in this application is Y-27632. In addition, examples of other ROCK inhibitors may include, but are not limited to, H-1152, Y-30141, Wf-536, HA-1077, hydroxy-HA-1077, GSK269962A and SB-772077-B.

[0074] MEK inhibitor refers to any substance that inhibits or reduces the intracellular MEK (mitogen-activated protein kinase kinase, Mitogen-activated protein kinase kinase, MAPKK) protein function or its signaling pathway, such as small molecules, siRNA, miRNA, antisense RNA, etc. MEK is a key kinase in the mitogen-activated protein kinase (MAPK) signaling pathway, which plays a vital role in cell growth, differentiation, survival and response to external stimuli. The method of inhibiting or reducing the function of MEK protein can be down-regulating, reducing, eliminating, inhibiting or reducing MEK gene expression or down-regulating, reducing, eliminating, inhibiting or reducing the activation level of MEK protein, peptide or polypeptide. The exemplary MEK inhibitor used in this application is PD0325901. In addition, examples of other MEK inhibitors may include, but are not limited to, binimetinib, cobimetinib, refametinib, selumetinib, trametinib, mirdametinib, AK-733, E6201, CI-1040, ATR-002, SHR7390, NFX-179, pimasertib, VS-6766, HL-085, FCN-159, LNP3794, CS3006, AS703988, TQ-B3234 and GDC-0623.

[0075] GSK3 inhibitors refer to any substance that inhibits or reduces the function of GSK3 (glycogen synthase kinase 3) protein or its signaling pathway in cells, such as small molecules, siRNA, miRNA, antisense RNA, etc. GSK3 is a multifunctional serine / threonine kinase that plays a role in a variety of cellular processes, including cell signaling, metabolic regulation, cell cycle control, cell differentiation, apoptosis, and development. The method of inhibiting or reducing the function of GSK3 protein can be downregulating, reducing, eliminating, inhibiting or reducing GSK3 gene expression or downregulating, reducing, eliminating, inhibiting or reducing the activation level of GSK3 protein, peptide or polypeptide. The exemplary GSK3 inhibitor used in this application is CHIR-99021. In addition, examples of other GSK3 inhibitors may include, but are not limited to, SB-216763, SB-415286, Tideglusib (NP-12), and 6-bromo-induced thiouracil (6-BIO).

[0076] CloneR2 is a culture medium supplement, which specifically supplements the nutrients necessary for cell culture and supports cell growth. The CloneR2 can be a commercial reagent purchased or a self-prepared solution.

[0077] In a specific embodiment, the CloneR2 can be present in any culture medium included in any stage of the method.

[0078] For example, the CloneR2 may be present in the establishment medium.

[0079] As another example, the method may comprise the use of a single cell culture medium, and the single cell growth medium may comprise CloneR2.

[0080] In a specific embodiment, the ROCK inhibitor in the culture medium can be Y-27632. In a specific embodiment, the MEK inhibitor can be PD0325901. In a specific embodiment, the GSK3 inhibitor can be CHIR-99021.

[0081] In a further embodiment, the establishment culture medium may further comprise human heregulin, growth factors and antioxidants.

[0082] In a specific embodiment, the human heregulin may be recombinant human heregulin β1. In a specific embodiment, the growth factor may be fibroblast growth factor 2 (FGF2). In a specific embodiment, the antioxidant may be sodium vitamin C phosphate.

[0083] As known to those skilled in the art, GSK3 inhibitors can generally activate the Wnt pathway, and conversely, Wnt activators can also be used as GSK3 inhibitors in the present invention.

[0084] Preferably, the working concentration of CloneR2 is 0.1×-10×, more preferably 0.5×-5×, and even more preferably 1×.

[0085] Preferably, the working concentration of the ROCK inhibitor, such as Y-27632, is 1-100 μM, more preferably 5-50 μM, and even more preferably 10 μM.

[0086] Preferably, the working concentration of the MEK inhibitor, such as PD0325901, is 0.1-10 μM, more preferably 0.3-2.5 μM, and even more preferably 0.5 μM.

[0087] Preferably, the working concentration of the GSK3 inhibitor, such as CHIR-99021, is 0.1-10 μM, more preferably 0.5-5 μM, and even more preferably 1 μM.

[0088] Preferably, the working concentration of human heregulin, such as recombinant human heregulin β1, is 1-100 ng / mL, more preferably 5-50 ng / mL, and even more preferably 20 ng / mL.

[0089] Preferably, the working concentration of the growth factor, such as fibroblast growth factor 2 (FGF2), is 10-1000 ng / mL, more preferably 50-500 ng / mL, and even more preferably 100 ng / mL.

[0090] Preferably, the working concentration of the antioxidant such as sodium vitamin C phosphate is 10-1000 μg / mL, more preferably 30-250 μg / mL, and even more preferably 50 μg / mL.

[0091] As those skilled in the art will know, in addition to the aforementioned selections, there are multiple selections of culture medium for establishment based on major categories, which specifically refer to the first level of culture medium, such as ROCK inhibitors, MEK inhibitors, GSK3 inhibitors based on targets, human heregulin and growth factors based on protein classification concepts, and antioxidants based on functional classification. The specific selection of culture medium for establishment will not be elaborated here.

[0092] In certain embodiments, the method may include culturing the pluripotent stem cells in a lineage culture medium before obtaining a single cell of the pluripotent stem cell. In a preferred embodiment, the contact may be 10-12 days. The 10-12 days may specifically be about 10 days, about 11 days, about 12 days, or any non-integer node therein. The pluripotent stem cells treated with the lineage culture medium have advantages in maintaining stemness and proliferation ability when used for monoclonal sorting.

[0093] In certain embodiments, the method may comprise: (1) Obtaining single cells of pluripotent stem cells; (2) culturing the single cell of the pluripotent stem cell obtained in step (1) in a single cell growth medium to form a single clone of the pluripotent stem cell; (3) Cultivating a single clone of the pluripotent stem cells obtained in step (2) in complete culture medium.

[0094] In certain embodiments, in step (1), single cells of pluripotent stem cells may be obtained by limiting dilution method, which may include physical separation and / or enzyme digestion of pluripotent stem cell clusters, and the specific steps are as follows: (a) The reprogrammed cells are divided into multiple cell clumps, and the cell clumps are digested in a centrifuge tube; (b) filtering the cells treated in step (a) using a cell screen; and (c) diluting the cells treated in step (b) to 2-200 cells / mL, preferably 5-120 cells / mL, more preferably 5-20 cells / mL, and even more preferably 5 cells / mL.

[0095] The reprogrammed cells may be pluripotent stem cells cultured in a lineage establishment medium. The pluripotent stem cells cultured in a lineage establishment medium may exist in a corresponding pluripotent stem cell culture.

[0096] The digestion can be accomplished by using a biological enzyme. The biological enzyme can be Accutase. The biological enzyme can be a commercial biological enzyme commonly used in the field (e.g., Accutase from Thermo).

[0097] In a further embodiment, in step (2), the single cell of the selected pluripotent stem cell is cultured in a single cell growth medium for 3-5 days, and the 3-5 days can specifically be about 3 days, about 4 days, about 5 days, or any non-integer node therein, preferably 4 days.

[0098] In a further embodiment, in step (3), the single clone of the pluripotent stem cell is cultured in the complete medium until the end of the line establishment. The complete medium may be a single cell growth medium that does not contain CloneR2.

[0099] In a preferred embodiment, the pluripotent stem cell may be an induced pluripotent stem cell (iPSC), preferably a human iPSC. In a further embodiment, the method for establishing a monoclonal cell line of an induced pluripotent stem cell (iPSC) may comprise the following steps: (1) Non-pluripotent cells are reprogrammed into iPSCs; (2) culturing the cells treated in step (1) in the aforementioned culture medium, preferably for 10-12 days; (3) obtaining single cells from the cells treated in step (2); (4) culturing the cells treated in step (3) in a single cell growth medium; and (5) Cultivating the cells treated in step (4) in complete medium, preferably until the end point of the line establishment.

[0100] In certain embodiments, the type of the culture medium can be determined according to the specific cell state. The culture medium used can be a common culture medium for culturing cells (e.g., minimum essential medium (MEM), Dulbecco's modified Eagle medium (DMEM), RPMI1640 medium, and F12 medium), or any culture medium suitable for pluripotent stem cells (e.g., NutriStem® hPSC XF medium, TeSRTM medium, TeSRTM 2 medium, TeSRTM-E8TM medium, TeSRTM-AOF medium, CTSTM Essential 8 medium), preferably DMEM or TeSRTM-AOF medium. Considering the subsequent therapeutic application of cells, a serum-free, xeno-free, animal-free, defined culture medium is preferred.

[0101] In a more specific embodiment, in step (4), the single cell culture medium can be the culture medium comprising CloneR2, examples of which are described above; or it can be the establishment culture medium comprising CloneR2.

[0102] In certain embodiments, the culture medium may contain supplementary ingredients such as B27 and non-essential amino acids.

[0103] In some embodiments, single cells can be seeded in a culture container coated with a matrix. Examples of the matrix include, but are not limited to, gelatin, laminin, fibronectin, collagen, etc. Specifically, the present invention uses vitronectin (Vitronectin XF™) or recombinant human laminin 521 (Laminin521) for coating.

[0104] As those skilled in the art have informed, monoclonal pluripotent stem cell lines derived from single cells have risks such as loss of stemness, low proliferation ability, high mortality, and genetic instability during the growth of single cells compared to pluripotent stem cells derived from cell clusters. However, due to the advantages of monoclonal cell lines in downstream differentiation production (such as high safety), the acquisition of monoclonal pluripotent stem cells has practical significance. The present invention provides a new method for establishing a monoclonal pluripotent stem cell line, which mainly achieves the purpose of establishing a monoclone by improving the culture medium. Multiple monoclonal pluripotent stem cells treated with the line establishment culture medium and the single cell growth culture medium have similar stemness to the pluripotent stem cells derived from cell clusters, and show similar downstream differentiation ability.

[0105] Reprogramming methods In a specific embodiment, the pluripotent stem cell may be an induced pluripotent stem cell (iPSC), preferably a human iPSC.

[0106] In the method for establishing a monoclonal cell line of induced pluripotent stem cells (iPSCs), the iPSCs may be obtained by transducing transcription factors into cells or by chemical reprogramming. The chemical reprogramming may include the step of contacting non-pluripotent cells with a reprogramming inducer.

[0107] As the starting point of reprogramming, the non-pluripotent cells can be fully differentiated cells, partially differentiated cells or a mixture of the two.

[0108] Examples of the non-pluripotent cells include, but are not limited to, skin cells such as epithelial cells, fibroblasts, blood and immune system cells such as T lymphocytes, urine cells, hormone-secreting cells such as pancreatic islet cells or adrenal medullary cells, breast cells, central nervous system (CNS) cells, glial cells such as astrocytes, peripheral nervous system (PNS) cells, muscle cells such as smooth muscle cells or cardiomyocytes, hematopoietic cells, bone cells, liver cells, fat cells, kidney cells, lung cells, chondrocytes, etc. The non-pluripotent cells may be a mixture of a variety of cells.

[0109] The source of the non-pluripotent cells of the present invention is a mammal. The mammals include, but are not limited to, rodents, primates, laboratory animals, pets, farm animals, such as mice, rats, rabbits, dogs, pigs, monkeys, and most preferably humans. There is no limitation on the age and gender of the mammal as the source of the cells. Preferably, the mammal is an adult mammal.

[0110] In the specific examples of the present application, the starting point of the reprogramming is adipose-derived mesenchymal stem cells (ADSC). The ADSC is an adult stem cell with multiple differentiation potentials, but compared with iPSC, ADSC still has many directions that cannot be differentiated, such as pancreatic islet cells and many types of epithelial cells. The ADSC can be human or non-human (such as monkey, mouse, rat, rabbit). Preferably, the ADSC is human.

[0111] When the iPSC obtained by the inducing agent composition or method of the present invention is used for therapeutic purposes, for example, when the iPSC or its derivatives such as differentiation products are used for transplantation, cells from healthy donors are preferably used as starting cells. In an optional embodiment, cells of an individual whose HLA type is the same or substantially the same as the subject to be treated can be used as starting cells. Methods for determining whether the HLA types of two individuals match to a certain extent so that they can be used as donors and recipients in transplantation, respectively, are known in the art.

[0112] Prior to carrying out the method of the present invention, the non-pluripotent cells may be maintained in a suitable culture medium. The type of culture medium is determined by the specific cell type used. Examples of culture medium that can be used include, but are not limited to, minimum essential medium (MEM) containing about 5% to about 20% fetal bovine serum, Dulbecco's modified Eagle medium (DMEM), RPMI1640 culture medium, and F12 culture medium.

[0113] In the method of the present invention, the contact between the non-pluripotent cells and the reprogramming inducer composition of the present invention is in vitro contact or ex vivo contact. The contact includes culturing the cells in a culture medium containing the reprogramming inducer composition. The culture can be a suspension culture or an adherent culture. Preferably, the culture is an adherent culture.

[0114] In a preferred embodiment, the step of contacting non-pluripotent cells with the reprogramming inducer composition of the present invention can be further divided into multiple stages, and in each stage, the cells are contacted with a portion of the small molecule compounds in the reprogramming inducer composition.

[0115] In a preferred embodiment, the step of contacting the non-pluripotent cells with a reprogramming inducing agent may include the following three stages: (1) contacting cells with a first-stage reprogramming inducing agent composition; (2) contacting the cells with a second-stage reprogramming inducer composition; and (3) contacting the cells with a third stage reprogramming inducer composition.

[0116] The first stage reprogramming inducer composition may include or consist of the following small molecule compounds: GSK3 inhibitor, NAD precursor and NAD catabolism inhibitor, TGF-β-RI / ALK5 inhibitor, RAR agonist, Hedgehog / Smoothened agonist, JNK inhibitor, histone methyltransferase inhibitor, JAK inhibitor, MLL inhibitor, AKT inhibitor, histone demethylase, growth factor bone morphogenetic protein. More specifically, the first stage reprogramming inducer composition may include the following small molecule compounds: CHIR-99021; lithium chloride; nicotinamide; ALK5 inhibitor II; aromatic retinoic acid; SAG; JNK-IN-8; EZM0414 TFA; EPZ5676; 3-deazaadenine A; ruxolitinib DZNep; VTP50469; AKT kinase inhibitor; vitamin C phosphate sodium; bone morphogenetic protein 4.

[0117] The second stage reprogramming inducer composition may contain or consist of the following small molecule compounds: histone demethylase, histone methyltransferase inhibitor, growth factor, GSK3 inhibitor, TGF-β-RI / ALK5 inhibitor, RAR agonist, Hedgehog / Smoothened agonist, AKT inhibitor, adenosine kinase inhibitor, JNK inhibitor, CK2 inhibitor, DNA methyltransferase inhibitor, JAK inhibitor, MAPK inhibitor, AMPK inhibitor, CBP / p300 inhibitor, MLL inhibitor. More specifically, the second stage reprogramming inducer composition can include the following small molecule compounds: sodium vitamin C phosphate; EPZ5676; 3-deazaadenine A; fibroblast growth factor 2; DZNep; FGF2; CHIR-99021; ALK5 inhibitor II; aromatic retinoic acid; SAG; AKT kinase inhibitor; 5-iodotuberculocidin; JNK-IN-8; CX4945; 5-azacytidine; ruxolitinib; damamod; Compound C; SGC-CBP30; VTP50469.

[0118] The third stage reprogramming inducer composition may contain the following small molecule compounds or be composed of the following small molecule compounds: GSK3 inhibitor, MEK inhibitor, ROCK inhibitor, TGFβ inhibitor, histone methyltransferase inhibitor, histone demethylase, histone demethylase inhibitor, histone deacetylase inhibitor, human heregulin. More specifically, the third stage reprogramming inducer composition may contain the following small molecule compounds: CHIR-99021; PD0325901; Y-27632; SB590885; EPZ5676; 3-deazaadenine A; Vitamin C phosphate sodium; DZNep; phenylcypromine hydrochloride; valproic acid; recombinant human heregulin β1. More specifically, the third stage reprogramming inducer composition may contain small molecule compounds of the following groups: (3A) CHIR-99021; PD0325901; Y-27632; SB590885; EPZ5676; 3-deazaadenine A; sodium vitamin C phosphate; 3-deazapromycin A; phenylcypromine hydrochloride; valproic acid; recombinant human heregulin β1; (3B) CHIR-99021; PD0325901; Y-27632; SB590885; sodium vitamin C phosphate; valproic acid; recombinant human heregulin β1; (3C) CHIR-99021; PD0325901; Y-27632; SB590885; sodium vitamin C phosphate; recombinant human heregulin β1.

[0119] In a further embodiment, the treatment time of the first stage reprogramming inducer composition can be 8-10 days.

[0120] In a further embodiment, the treatment time of the second stage reprogramming inducer composition can be 8-12 days.

[0121] In a further embodiment, the treatment time of the third stage reprogramming inducer composition can be 10-12 days. Further, the treatment time of 3A can be 3-5 days, preferably 4 days. The treatment time of 3B can be 3-5 days, preferably 4 days. The treatment time of 3C can be 2-4 days.

[0122] As described above, the contact can be performed in a culture medium. The culture medium used in the method of the present invention can be any culture medium suitable for pluripotent stem cells (e.g., NutriStem® hPSC XF culture medium, TeSRTM culture medium, TeSRTM2 culture medium, TeSRTM -E8TM culture medium, TeSRTM-AOF culture medium, CTS TM Essential 8 culture medium), preferably DMEM or TeSRTM-AOF culture medium. Considering the subsequent therapeutic application of cells, serum-free, xeno-free animal component, defined culture medium is preferred.

[0123] iPSCs are included in the cell culture after the aforementioned reprogramming. The qualitative or quantitative method for detecting iPSCs can be selected from alkaline phosphatase detection, immunofluorescence staining detection, flow cytometry detection, and quantitative PCR detection. For example, the successful acquisition of iPSCs can be confirmed by markers of cell pluripotency, wherein the markers include but are not limited to Oct-3, Oct-4, SSEA-3, SSEA-4, SOX2, TRA-1-61, TRA-1-81 and / or Nanog. The function of iPSCs can also be detected by differentiation experiments.

[0124] use The monoclonal cell lines of pluripotent stem cells obtained by the method of the present invention can be used for various purposes.

[0125] In certain embodiments, the monoclonal cell line of the pluripotent stem cells can be induced to differentiate into a variety of cell types, tissues or organoids for predetermined purposes, including non-therapeutic purposes and therapeutic purposes.

[0126] In certain embodiments, the monoclonal cell line of the pluripotent stem cells can be formulated for therapeutic purposes, such as further differentiation into different functional cells for transplantation cell therapy.

[0127] In certain embodiments, the monoclonal cell line of the pluripotent stem cells can be used for research purposes. For example, the monoclonal cell line of the pluripotent stem cells, its progeny or differentiated cells can be used for the study of cell differentiation and cell function, for the effectiveness and safety screening of drugs, etc.

[0128] In a specific embodiment, the monoclonal cells are used to differentiate into pancreatic islet cells. Specifically, the differentiation preference is pancreatic β cells.

[0129] In certain embodiments, differentiating the monoclonal cell line of pluripotent stem cells into pancreatic islet cells comprises the step of contacting the monoclonal cell line with a differentiation inducing agent, which comprises the following six stages: (1) contacting cells with a first-stage differentiation inducing agent composition; (2) contacting the cells with a second stage differentiation inducing agent composition; (3) contacting the cells with a third stage differentiation inducing agent composition; (4) contacting the cells with a fourth stage differentiation inducing agent composition; (5) contacting the cells with a fifth stage differentiation inducing agent composition; and (6) contacting the cells with a sixth stage differentiation inducing agent composition.

[0130] The first stage differentiation inducer composition may contain the following small molecule compounds or be composed of the following small molecule compounds: TGF-β activator, GSK-3α / β inhibitor, PI3K inhibitor, ROCK inhibitor. More specifically, the first stage differentiation inducer composition may contain the following small molecule compounds: Activin A; CHIR-99021; PI-103; Y-27632. More specifically, the first stage differentiation inducer composition may contain the following groups of small molecule compounds: (S1D1) Activin A; CHIR-99021; PI-103; Y-27632; (S1D2-D4) Activin A.

[0131] The second stage differentiation inducer composition may include or consist of the following small molecule compounds: ALK5 inhibitor; Wnt pathway inhibitor; growth factor. More specifically, the second stage differentiation inducer composition may include the following small molecule compounds: SB431542; WntC59; keratinocyte growth factor.

[0132] The third stage differentiation inducer composition may include or consist of the following small molecule compounds: BMP type I receptor inhibitor; retinoic acid; Smo antagonist; Wnt pathway inhibitor. More specifically, the third stage differentiation inducer composition may include the following small molecule compounds: LDN-193189; retinoic acid; Sant1; WntC59.

[0133] The fourth stage differentiation inducer composition may contain the following small molecule compounds or be composed of the following small molecule compounds: sirtuins inhibitors; growth factors; PKC activators; Smo antagonists; ROCK inhibitors. More specifically, the fourth stage differentiation inducer composition may contain the following small molecule compounds: nicotinamide; epidermal growth factor; TPB; Sant1; Y-27632. More specifically, the fourth stage differentiation inducer composition may contain the following groups of small molecule compounds: (S4D1) Nicotinamide; epidermal growth factor; TPB; Sant1; Y-27632; (S4D2-D6) Nicotinamide; epidermal growth factor; TPB; Sant1.

[0134] The fifth stage differentiation inducer composition may contain the following small molecule compounds or be composed of the following small molecule compounds: BMP signal inhibitor; anticoagulant; thyroid hormone; TGFβR-1 / ALK5 inhibitor; ROCK inhibitor; Wnt pathway inhibitor; γ-secretase inhibitor; multi-signal pathway activator. More specifically, the fifth stage differentiation inducer composition may contain the following groups of small molecule compounds: (S5D1-D3) LDN-193189; heparin sodium; triiodothyronine; ALK5 inhibitor II; Y-27632; WntC59; XXI; ISX9; (S5D4-D6) LDN-193189; heparin sodium; triiodothyronine; ALK5 inhibitor II; Y-27632; WntC59; XXI.

[0135] The sixth stage differentiation inducer composition may contain the following small molecule compounds or be composed of the following small molecule compounds: TGFβR-1 / ALK5 inhibitor; anticoagulant; thyroid hormone; Axl inhibitor; ROS inhibitor. More specifically, the sixth stage differentiation inducer composition may contain the following small molecule compounds: ALK5 inhibitor II; heparin sodium; triiodothyronine; R428; acetylcysteine; zinc sulfate.

[0136] In a further embodiment, the treatment time of the first stage differentiation inducer composition can be 3-5 days, preferably 4 days. Furthermore, the treatment time of S1D1 can be 0.5-1.5 days, preferably 1 day. The treatment time of S1D2 can be 2-4 days, preferably 3 days.

[0137] In a further embodiment, the treatment time of the second stage differentiation inducing agent composition can be 1-3 days, preferably 2 days.

[0138] In a further embodiment, the treatment time of the third stage differentiation inducing agent composition can be 3-5 days, preferably 4 days.

[0139] In a further embodiment, the treatment time of the fourth stage differentiation inducer composition can be 5-7 days, preferably 6 days. Furthermore, the treatment time of S4D1 can be 0.5-1.5 days, preferably 1 day. The treatment time of S4D2 can be 4-6 days, preferably 5 days.

[0140] In a further embodiment, the treatment time of the fifth stage differentiation inducer composition can be 5-7 days, preferably 6 days. Furthermore, the treatment time of S5D1 can be 2-4 days, preferably 3 days. The treatment time of S5D4 can be 2-4 days, preferably 3 days.

[0141] In a further embodiment, the treatment time of the sixth stage differentiation inducer composition can be 1-3 days, preferably 2 days.

[0142] Without intending to be bound by any theory, the following embodiments are merely intended to illustrate various technical solutions of the present invention and are not intended to limit the scope of the present invention.

[0143] For specific ingredients that appear multiple times in the following examples, if the manufacturer and product number are not indicated, the manufacturer and product number indicated when they first appear shall prevail. Example

[0144] Example 1 Reprogramming non-pluripotent cells First, the inventors derived induced pluripotent stem cells (iPSCs) from non-pluripotent stem cells using a reprogramming approach.

[0145] This example uses adipose-derived mesenchymal stem cells (ADSCs) cultured in serum-free and feeder-free conditions.

[0146] The ADSCs were plated in a 12-well plate at 1×104 cells / well, and reprogramming was started on the next day. Specifically, S1 medium containing the first-stage reprogramming induction composition was added in the S1 stage, and cultured in a 37°C, 5% CO2, 5% O2 incubator for 8-10 days; after the S1 stage, the S2 medium containing the second-stage reprogramming induction composition was replaced in the S2 stage, and cultured in a 37°C, 5% CO2, 21% O2 incubator for 8-12 days; after the S2 stage, the S3 medium containing the third-stage reprogramming induction composition was replaced in the S3 stage, and cultured in a 37°C, 5% CO2, 21% O2 incubator for 10-12 days, including 4 days in S3A medium, 4 days in S3B medium, and finally 2-4 days in S3C medium.

[0147] In the following concentration section, "%" refers to the volume concentration of the specific substance.

[0148] The composition of the S1 medium is: based on KnockOut DMEM (Gibco, Cat#10829018) as the basal medium, and also includes the following working concentration components: 1% KnockOut™ serum replacement (Gibco, Cat#10828028), 2% B-27™ supplement (Gibco, Cat#17504-044), 1% GlutaMax (Gibco, Cat#35050079), 1% non-essential amino acids (Gibco, Cat#11140050), 50 μg / mL sodium vitamin C phosphate (Sigma, Cat#49752), 5 mM lithium chloride (Sigma-Aldrich, Cat# L4408), 1 mM niacinamide (STEMCELL, Cat#07154), 5 μM CHIR-99021 (selleck, Cat#S1263), 10 μM ALK5 inhibitor II, 2 μM Aroretinoic acid (MCE, Cat# HY-15682), 0.5 μM SAG (MCE, Cat# HY-12848), 2 μM EPZ5676 (MCE, Cat# HY-15593), 0.2 μM JNK-IN-8 (MCE, Cat# HY-13319), 0.2 μM EZM0414 TFA (MCE, Cat# HY-136328), 0.05 μM 3-deazaadenine A (MCE, Cat# HY-12186), 1 μM ruxolitinib (MCE, Cat# HY-50856), 0.5 μM VTP50469 (MCE, Cat# HY-114162), 1 μM AKT kinase inhibitor (Taosu, Cat# T10276), and 20 ng / ml Bone morphogenetic protein 4 (PeproTech, Cat# AF-120-05ET-500ug), the concentrations mentioned are all final concentrations.

[0149] The composition of the S2 medium is: based on KnockOut DMEM (Gibco, Cat#10829018) as the basal medium, and also includes the following working concentration components: 2% B-27™ supplement (Gibco, Cat#17504-044), 1% GlutaMax (Gibco, Cat#17504-044), 1% non-essential amino acids (Gibco, Cat#11140050), 50 μg / mL vitamin C phosphate sodium (Sigma, Cat#49752), 2 μM EPZ5676 (MCE, Cat# HY-15593), 0.2 μM 3-deazaadenine A (MCE, Cat# HY-12186), 200 ng / mL fibroblast growth factor 2 (Origene, Cat#TP750002), 5 μM CHIR-99021 (selleck, Cat# S1263), 10 μM ALK5 inhibitor II, 2 μM aryretinoic acid (MCE, Cat# HY-15682), 0.5 μM SAG (MCE, Cat# HY-12848), 0.2 μM AKT kinase inhibitor (Taosu, Cat# T10276), 0.5 μM 5-iodotuberculocidin (MCE, Cat# HY-15424), 0.5 μM JNK-IN-8 (MCE, Cat# HY-13319), 1 μM CX4945 (MCE, Cat# HY-50855), 2 μM 5-azacytidine (MCE, Cat# HY-10586), 1 μM ruxolitinib (MCE, Cat# HY-50856). Damaimod (MCE, Cat# HY-10320), 0.5 μM Compound C (MCE, Cat# HY-13418A), 2 μM SGC-CBP30 (MCE, Cat# HY-15826) and 0.5 μM VTP50469 (MCE, Cat# HY-114162), the concentrations mentioned are the final working concentrations.

[0150] The composition of the S3A medium is: based on KnockOut DMEM (Gibco, Cat#10829018) as the basal medium, and also includes the following working concentration components: 5% KnockOut™ serum replacement (Gibco, Cat#10828028), 2% B-27™ supplement (Gibco, Cat#17504-044), 1% GlutaMax (Gibco, Cat#17504-044), 1% non-essential amino acids (Gibco, Cat#11140050), 50 μg / mL vitamin C phosphate sodium (Sigma, Cat#49752), 20 ng / mL recombinant human heregulin β1 (PeproTech, Cat#100-03), 1 μM CHIR-99021 (selleck, Cat#S1263), 0.5 μM SB590885 (Selleck, Cat#S2220), 10 μM Y-27632 (Selleck, Cat#S1049), 1 μM PD0325901 (MCE, Cat#HY-10254), 10 μM phencyclidine hydrochloride (MCE, Cat#HY-17447A), 1000 μM valproic acid (MCE, Cat#HY-10585), 0.2 μM 5-azacytidine (MCE, Cat# HY-12186) and 2 μM EPZ5676 (MCE, Cat# HY-15593), the above concentrations are the final working concentrations.

[0151] The composition of the S3B medium is: based on KnockOut DMEM (Gibco, Cat#10829018) as the basal medium, and also includes the following working concentration components: 5% KnockOut™ serum replacement (Gibco, Cat#10828028), 2% B-27™ supplement (Gibco, Cat#17504-044), 1% GlutaMax (Gibco, Cat#17504-044), 1% non-essential amino acids (Gibco, Cat#11140050), 50 μg / mL vitamin C phosphate sodium (Sigma, Cat#49752), 20 ng / mL recombinant human heregulin β1 (PeproTech, Cat#100-03), 1 μM CHIR-99021 (selleck, Cat#S1263), 0.5 μM SB590885 (Selleck, Cat#S2220), 10 μM Y-27632 (Selleck, Cat#S1049), 1 μM PD0325901 (MCE, Cat#HY-10254) and 500 μM valproic acid (MCE, Cat#HY-10585), the concentrations are all final working concentrations.

[0152] The composition of the S3C medium is: based on KnockOut DMEM (Gibco, Cat#10829018) as the basal medium, and also includes the following working concentration components: 5% KnockOut™ serum replacement (Gibco, Cat#10828028), 2% B-27™ supplement (Gibco, Cat#17504-044), 1% GlutaMax (Gibco, Cat#17504-044), 1% non-essential amino acids (Gibco, Cat#11140050), 50 μg / mL sodium vitamin C phosphate (Sigma, Cat#49752), 20 ng / mL recombinant human heregulin β1 (PeproTech, Cat#100-03), 1 μM CHIR-99021 (selleck, Cat#S1263), 0.5 μM SB590885 (Selleck, Cat#S2220), 10 μM Y-27632 (Selleck, Cat#S1049) and 1 μM PD0325901 (MCE, Cat#HY-10254), the concentrations mentioned are final working concentrations.

[0153] After the S3 culture was completed, a typical early iPSC clone morphology with a dense monolayer and clear boundaries appeared, confirming that human pluripotent stem cells had been obtained.

[0154] Example 2 Monoclonal iPSC line establishment method and comparison of different dilution concentrations After obtaining iPSCs, the iPSCs are first cultured using the culture medium for establishing the line protected in the present application, and then single cells are obtained from the iPSCs using different limiting dilution ratios to explore the most appropriate limiting dilution ratio.

[0155] The cells obtained after the S3 stage in Example 1 were resuspended in the establishment medium and seeded into a six-well plate coated with recombinant human laminin 521 (Laminin521) (stem cell, Cat#200-0117) at a subculture ratio of 1:1 to 1:15, and cultured in an incubator at 37°C, 5% CO2, 21% O2 for 10-12 days.

[0156] The composition of the culture medium is: KnockOut DMEM (Gibco, Cat#10829018) as the basal medium, and also includes the following working concentration components: 2% B-27™ Supplement (Gibco, Cat#17504-044), 1% GlutaMax (Gibco, Cat#17504-044), 1% Nonessential Amino Acids (Gibco, Cat#11140050), 4% KnockOut™ Serum Replacement (Gibco, Cat#10828028), 50 μg / mL Vitamin C Phosphate Sodium (Sigma, Cat#49752), 1 μM CHIR-99021 (selleck, Cat#S1263), 0.5 μM PD0325901 (MCE, Cat#HY-10254), 10 μM Y-27632 (Selleck, Cat#S1049), 20 ng / mL recombinant human heregulin β1 (PeproTech, Cat#100-03) and 100 ng / mL fibroblast growth factor 2 (Origene, Cat#TP750002), all of which are final working concentrations.

[0157] Single cell selection and establishment of human pluripotent stem cell lines ① After the cells obtained after the S3 stage in Example 1 are cultured in the establishment medium, obvious clones appear. Use a sterile glass needle or pipette tip to divide the clones into small clones of appropriate sizes (one clone is divided into 15-20 small clones of relatively uniform size): A portion of the small clones were seeded onto 24-well plates coated with vitronectin (Vitronectin XF™) or recombinant human laminin 521 (Laminin521) 1-4 days in advance, and cultured for 1 day in TeSRTM-AOF complete medium containing Y-27632. After further culture in TeSRTM-AOF complete medium for 4-6 days, cell cluster-derived iPSCs were obtained.

[0158] The other small clones are transferred to the prepared centrifuge tubes by pipette for the following steps: ② Centrifuge at 100-300 g for 3-5 minutes or remove the supernatant after sedimentation, add 100-600 μL Accutase (thermo, Cat# 00-4555-56), mix well and place in the incubator for digestion for 15-20 minutes.

[0159] ③ After a large number of single cells are seen to fall off under the microscope, use a pipette to gently blow to completely remove the single cells, add an equal volume of single cell growth medium to resuspend, filter the cell suspension with a 40 μm cell sieve to remove large cells, and centrifuge the filtered cell suspension at 300-500g for 3-5 minutes.

[0160] ④ Remove the supernatant, add a small amount of single cell growth medium to resuspend, count, and use the gradient dilution principle to continuously dilute the cell suspension to a very low density of 5-120 cells / mL, and inoculate it in a 96-well plate coated with vitronectin (VitronectinXF™) or recombinant human laminin 521 (Laminin521) 1-4 days in advance, and add 0.1 mL of cell resuspension to each well. After 4 days of continuous culture without changing the medium, the culture medium was replaced with TeSRTM-AOF complete medium. On the day after inoculation, the wells where single cells appeared were marked under microscopic conditions, and continued to track until they grew into a single clone. Continue to culture until the clone grows to a diameter of about 1200-1600 μm and then pass it on to the next generation to obtain monoclonal iPSC.

[0161] The single cell growth medium is composed of: adding 1×CloneR2 (stem cell, Cat#100-0691) to TeSRTM-AOF (stem cell, Cat#100-0401) complete medium.

[0162] The obtained monoclonal iPSCs were subjected to karyotype analysis, which was performed by Deyou Medical Testing Laboratory Co., Ltd. using the standard G-banding protocol.

[0163] like Figure 3As shown in Table 1, in step ④, when the dilution density was 120 cells / mL, 60 cells / mL, 20 cells / mL, and 10 cells / mL, the proportion of polyclonal cells in the wells gradually decreased. When the dilution density was 5 cells / mL, only monoclonal cells appeared in the wells.

[0164] Table 1 Relationship between limiting dilution density and the proportion of monoclonal clones in a well

[0165] Note: The denominator of the monoclonal ratio represents the number of inoculated wells, and the numerator represents the number of wells with monoclonal growth; the denominator of the polyclonal ratio represents the number of inoculated wells, and the numerator represents the number of wells with polyclonal growth; " / " means that the dilution density test was not performed due to insufficient cell quantity; "None" means that the number of wells with monoclonal or polyclonal growth is 0.

[0166] The obtained monoclonal iPSCs were analyzed by flow cytometry. Figure 4-Figure 9 As shown, Nanog, OCT4, SOX-2, SSEA, Tra-1-60, and Tra-1-81 are markers of cell pluripotency, and the results of stemness antibody analysis of monoclonal iPSCs are similar to those of cell cluster-derived iPSCs.

[0167] Example 3 Comparison of single cell growth medium additives After studying the most appropriate limiting dilution ratio, the inventors investigated the effects of different additives (CloneR2 or Y-27632) in the single cell growth medium on the growth of iPSC single cells.

[0168] ① After the cells obtained after the S3 stage in Example 1 are cultured in the establishment medium, obvious clones appear. Use a sterile glass needle or pipette to divide the clones into small clones of appropriate size, and use a pipette to transfer the small clones to a centrifuge tube prepared in advance. Centrifuge at 100-300 g for 3-5 minutes or after sedimentation, remove the supernatant, add 100-600 μL Accutase (thermo, Cat# 00-4555-56), mix well, and place in an incubator for digestion for 15-20 minutes.

[0169] ② After a large number of single cells are observed to have fallen off under the microscope, use a pipette to gently blow to completely remove the single cells, add an equal volume of single cell growth medium to resuspend the cells, filter the cell suspension with a 40 μm cell sieve to remove large cells, and centrifuge the filtered cell suspension at 300-500g for 3-5 minutes.

[0170] ③ Remove the supernatant, add a small amount of TeSRTM-AOF (stem cell, Cat#100-0401) complete culture medium to resuspend, and use culture medium with different components for subsequent single cell isolation and culture after counting: 1. Dilute the cell suspension serially to 10 cells / mL using TeSRTM-AOF complete medium containing Y-27632 and without CloneR2, inoculate into 96-well plates, and add 0.1 mL of cell resuspension to each well.

[0171] 2. Dilute the cell suspension serially to 10 cells / mL using single cell growth medium containing CloneR2, inoculate into 96-well plates, and add 0.1 mL of cell resuspension to each well.

[0172] The 96-well plates were coated with vitronectin (Vitronectin XF™) or recombinant human laminin 521 (Laminin521) 1-4 days in advance.

[0173] ④ After 4 days of continuous culture without changing the medium, the culture medium was replaced with TeSRTM-AOF complete medium. On the day after inoculation, the wells where single cells appeared were marked under microscopic conditions and continued to track until they grew into a single clone.

[0174] The number of monoclones obtained in the two single cell growth media was counted and the monoclonal formation efficiency was calculated. The monoclones were cultured and subcultured continuously to detect whether different monoclones could maintain normal karyotype and good stemness after continuous subculture.

[0175] As shown in Table 2 and Fig.10 As shown in Table 3, the monoclonal formation efficiency of the lines established using the single cell growth medium containing Y-27632 is 2-10%, while the monoclonal formation efficiency of the lines established using the single cell growth medium containing CloneR2 is 10-25%. The efficiency of CloneR2 is increased by 2.5-6.5 times. As shown in Table 3, the monoclonal iPSCs established using the single cell growth medium containing Y-27632 / CloneR2 all express the core genes of pluripotent stem cells after continuous passage, and the positive rates of Nanog, OCT4, SSEA4, TRA-1-60, and TRA-1-81 are all >97%. As shown in Tables 4 and 5, the monoclonal iPSCs established using the single cell growth medium containing Y-27632 have 2 abnormal karyotypes after continuous passage, while the monoclonal iPSCs established using the single cell growth medium containing CloneR2 have normal karyotypes after continuous passage.

[0176] Table 2 Effects of different additives in single cell growth medium on the efficiency of monoclonal formation

[0177] Table 3 Effects of different additives in single cell growth medium on the stemness of monoclonal iPSCs (%)

[0178] Table 4 Effect of adding Y-27632 to the single cell growth medium on the karyotype of monoclonal iPSCs

[0179] Table 5 Effect of adding CloneR2 to the single cell growth medium on the karyotype of monoclonal iPSCs

[0180] Example 4 Comparison of single cell isolation methods After studying different limiting dilution ratios and different additives to single-cell growth culture media, the inventors studied different single-cell isolation methods, specifically studying the effects of limiting dilution and capillary methods on iPSC single-cell growth.

[0181] ① After the cells obtained at the S3 stage in Example 1 are cultured in the establishment medium, obvious clones appear. Use a sterile glass needle or pipette to divide the clones into small clones of appropriate size, and use a pipette to transfer the small clones to a centrifuge tube prepared in advance. Centrifuge at 100-300 g for 3-5 minutes or remove the supernatant after sedimentation, add 100-600 μL Accutase (thermo, Cat# 00-4555-56), mix well, and place in an incubator for digestion for 1-15 minutes.

[0182] ② After a large number of single cells are observed to have fallen off under the microscope, use a pipette to gently blow to completely remove the single cells, add an equal volume of single cell growth medium to resuspend the cells, filter the cell suspension with a 40 μm cell sieve to remove large cells, and centrifuge the filtered cell suspension at 300-500g for 3-5 minutes.

[0183] ③ Remove the supernatant, add a small amount of single cell growth medium to resuspend, count and use different methods to separate single cells: 1. Capillary: dilute the cell suspension to 100 cells / mL, pipette 1 mL into a culture dish, observe under a microscope, pipette one cell with a capillary and add it to a 96-well plate; 2. Limiting dilution: Using the gradient dilution principle, the cell suspension was diluted to a very low density of 5-20 cells / mL, inoculated into a 96-well plate, and 0.1 mL of cell resuspension was added to each well.

[0184] The 96-well plates were coated with vitronectin (Vitronectin XF™) or recombinant human laminin 521 (Laminin521) 1-4 days in advance.

[0185] ④ After 4 days of continuous culture without changing the medium, the culture medium was replaced with TeSRTM-AOF complete medium. On the day after inoculation, the wells where single cells appeared were marked under microscopic conditions and continued to track until they grew into a single clone.

[0186] The numbers of single clones obtained by the two single-cell isolation methods were counted, and the efficiency of monoclonal formation was calculated.

[0187] As shown in Table 6 and Fig.11 As shown, the monoclonal formation efficiency of the lines established using the capillary single cell isolation method was 0-4%, while the monoclonal formation efficiency of the lines established using the limiting dilution method was 4-24%.

[0188] Table 6 Effects of different single cell isolation methods on the efficiency of monoclonal formation

[0189] Example 5 Small molecule formula for establishing culture medium Next, the inventors explored the effects of the presence or absence of ROCK inhibitors, MEK inhibitors, and GSK3 inhibitors in the culture medium on cell proliferation, and also explored the effects of antioxidants.

[0190] iPSCs from two different reprogramming batches resuspended in different composition of the establishment culture medium (see Table 7 for details) were inoculated onto 24-well plates coated with recombinant human laminin 521 (Laminin521) (stem cell, Cat#200-0117) and cultured in a 37°C, 5% CO2 incubator for 5-14 days. When obvious clones appeared, take photos of the clone morphology of different experimental groups and count the number of clones obtained.

[0191] Table 7 Grouping of small molecule formulas for culture medium

[0192] Note: “ / ” means no small molecule is added, " represents the addition of this small molecule.

[0193] The cell clones cultured in different culture medium were subjected to flow cytometry detection of stemness marker OCT4. Accutase was used to digest the 7 groups of cell clones into single cells, fixed overnight with fixative, washed with washing solution on the next day, incubated overnight with primary antibody, washed with washing solution, incubated with secondary antibody for 2 hours, and then washed with washing solution for detection after incubation. This experiment was detected by flow cytometer BD Calibur and analyzed with FlowJo software.

[0194] The proliferation status of the first batch of iPSCs is as follows Fig.12 As shown, experimental group 3 without Y-27632 and experimental group 7 without all small molecules did not grow obvious clones; experimental group 6 with only Y-27632 grew dense but small clones; experimental group 2 without CHIR-99021 grew clones with irregular morphology and not dense; experimental group 4 without PD0325901 grew clones that were small and cells in the center of the clones were prone to death; experimental group 5 with all small molecules grew clones that were large, with clear edges and a dense single layer, and experimental group 1 without sodium vitamin C phosphate grew clones that were slightly worse than those in experimental group 5, but better than those in other experimental groups.

[0195] like Fig.13 As shown, experimental group 5 had the largest number of clones, followed by experimental group 1. Fig.14 As shown, experimental groups 1, 5, and 6 had the most OCT4+ cells.

[0196] The proliferation status of the second batch of iPSCs is as follows Fig.16 As shown, in experimental group 7 without adding all small molecules, cells died and no obvious clones grew; in experimental group 3 without adding Y-27632, only a small number of clones grew; in experimental group 4 without adding PD0325901 and experimental group 6 with only adding Y-27632, the clones grown were not dense and the contact between cells was not close; in experimental group 1 without adding sodium vitamin C phosphate, experimental group 2 without adding CHIR-99021 and experimental group 5 with adding all small molecules, the clones grown were dense and numerous.

[0197] like Fig.17 and Fig.18 As shown, experimental group 5 had the most OCT4+ cells.

[0198] Comprehensively judging, the experimental group 5 with all small molecules added and the experimental group 1 without sodium vitamin C phosphate added had the best effect. Those skilled in the art can realize from this embodiment that in order to ensure the stemness and proliferation ability of the pluripotent stem cells, it is essential to add ROCK inhibitor, MEK inhibitor and GSK3 inhibitor to the culture medium at the same time.

[0199] In summary, the optimal formula of the culture medium is: KnockOut DMEM + 2% B-27™ supplement + 1% GlutaMax + 1% non-essential amino acids + 4% KnockOut™ serum replacement + 20 ng / mL recombinant human heregulin β1 + 100 ng / mL fibroblast growth factor 2 + 50 μg / mL sodium vitamin C phosphate + 1 μM CHIR-99021 + 10 μM Y-27632 + 0.5 μM PD0325901. The above concentrations are all final working concentrations.

[0200] Example 6 Comparison of single cell growth media Next, the inventors explored the effects of the presence or absence of CloneR2 in the single-cell culture medium and the type of basal culture medium on the growth of iPSC single cells.

[0201] ① After the cells obtained after the S3 stage in Example 1 are cultured in the establishment medium, obvious clones appear. Use a sterile glass needle or pipette to divide the clones into small clones of appropriate sizes, and use a pipette to transfer three small clones from different clones (labeled as 1#, 2#, and 3#) to a centrifuge tube prepared in advance. Centrifuge at 100-300 g for 3-5 minutes or after sedimentation, remove the supernatant, add 100-600 μL Accutase (thermo, Cat# 00-4555-56), mix well, and place in an incubator for digestion for 1-15 minutes.

[0202] ② After a large number of single cells are observed to have fallen off under the microscope, use a pipette to gently blow to completely remove the single cells, add an equal volume of single cell growth medium to resuspend the cells, filter the cell suspension with a 40 μm cell sieve to remove large cells, and centrifuge the filtered cell suspension at 300-500g for 3-5 minutes.

[0203] ③ Remove the supernatant, add a small amount of TeSRTM-AOF (stem cell, Cat#100-0401) complete medium to resuspend, and use single cell growth medium with different components for subsequent single cell isolation and culture after counting: 1. Dilute the cell suspension serially to 10 cells / mL with TeSRTM-AOF complete medium containing CloneR2, inoculate into 96-well plates, and add 0.1 mL of cell resuspension to each well.

[0204] 2. Serially dilute the cell suspension to 10 cells / mL using the CloneR2 culture medium, inoculate into 96-well plates, and add 0.1 mL of cell suspension to each well.

[0205] 3. Dilute the cell suspension serially to 10 cells / mL with the culture medium, inoculate into 96-well plates, and add 0.1 mL of cell suspension to each well.

[0206] 4. Dilute the cell suspension serially to 10 cells / mL with TeSRTM-AOF complete medium, inoculate into 96-well plates, and add 0.1 mL of cell resuspension to each well.

[0207] The 96-well plates were coated with vitronectin (Vitronectin XF™) or recombinant human laminin 521 (Laminin521) 1-4 days in advance.

[0208] The culture medium for establishing a line is a culture medium for establishing a line containing a ROCK inhibitor, a MEK inhibitor and a GSK3 inhibitor.

[0209] ④ After 4 days of continuous culture without changing the medium, replace the medium in cells 1 and 4 with TeSRTM-AOF complete medium. Replace the medium in cells 2 and 3 with the establishment medium that does not contain CloneR2. On the day after inoculation, mark the wells where single cells appear under microscopic conditions and continue to track until they grow into a single clone.

[0210] The number of single clones obtained in the four single-cell growth media was counted.

[0211] like Fig.19 As shown, the numbers of monoclones formed by clone 1# in the four single cell growth mediums are 1, 1, 0, 0, respectively; the numbers of monoclones formed by clone 2# in the four single cell growth mediums are 3, 3, 0, 0, respectively; and the numbers of monoclones formed by clone 3# in the four single cell growth mediums are 6, 9, 2, 0, respectively. Therefore, using TeSRTM-AOF complete medium containing CloneR2 or establishment medium containing CloneR2 can improve the survival of single cells and obtain more monoclones.

[0212] Example 7 Pancreatic Islet Differentiation Protocol After studying the effects of the above factors on the growth of iPSC single cells, the inventors studied the use of monoclonal iPSCs to differentiate downstream cells, specifically pancreatic islet cells.

[0213] The monoclonal iPSCs used for islet differentiation were cultured in a lineage medium containing a ROCK inhibitor, a MEK inhibitor, and a GSK3 inhibitor, and then isolated single cells by a limiting dilution method and cultured in a single cell growth medium containing CloneR2 to obtain the monoclonal iPSCs.

[0214] The monoclonal iPSCs were plated in a 12-well plate at 5.5×105 cells / well, and pancreatic islet differentiation was started on the next day. Specifically, S1D1 medium containing the first-stage differentiation induction composition was added at the S1 stage, and after culturing in a 37°C, 5% CO2 incubator for 1 day, it was replaced with S1D2 medium containing the first-stage differentiation induction composition, and continued to be cultured in a 37°C, 5% CO2 incubator for 3 days.

[0215] After the S1 stage, the medium was replaced with an S2 medium containing the second-stage differentiation-inducing composition at the S2 stage, and the cells were cultured in an incubator at 37° C. and 5% CO 2 for 2 days.

[0216] After the S2 stage, the medium was replaced with an S3 medium containing the third stage differentiation inducing composition at the S3 stage, and cultured in an incubator at 37° C. and 5% CO 2 for 4 days.

[0217] After the S3 stage, the plate was transferred and the S4 stage was entered. 0.5 mL Accutase was added to each well and the plate was placed in an incubator for digestion for about 5 minutes. After a large number of cells were observed to fall off under the microscope, the 12-well plate was tapped to completely remove the cells and the cell suspension was transferred to a 50 mL centrifuge tube. After centrifugation at 400 g for 3 minutes, the supernatant was discarded. The cells were resuspended in S4D1 medium containing the fourth stage differentiation induction composition, and the cell resuspension was filtered with a 40 μm cell sieve to remove large cells. The cells were inoculated into AggreWell 400 6-well (Stemcell, Cat#34425) at a cell density of 1×107 cells / well for sphere formation, and the volume of each well was supplemented to 2 mL. The cells were tapped crosswise to shake well and cultured in an incubator at 37°C, 5% CO2 for 1 day. The next day, the AggreWell 400 6-well was flattened to allow most of the spheroid cells to fall off, and the cell spheroid suspension was transferred to a 50 mL centrifuge tube. After centrifugation at 100 g for 30 s, the supernatant was discarded. The cell spheroids were resuspended in S4D2 medium containing the fourth stage differentiation induction composition and evenly inoculated into low-adsorption cell culture plates (Greiner, Cat#657185) (1 well of cell spheroids was inoculated into 1 well of a low-adsorption cell culture plate), and cultured in a shaking incubator for 1 day. The next day, the suspension culture plate was shaken in a circle in the clean bench to make the cell spheroids gather in the middle, and the flocs around the cell spheroids were observed. The flocs were gently sucked away, and half of the original culture medium was sucked away along the top liquid surface, and then 3 mL of S4D2 culture medium was added, and the culture was continued in a shaking incubator for 4 days. During this period, the S4D2 culture medium was changed every two days.

[0218] After the S4 stage, the medium was replaced with S5D1 medium containing the fifth stage differentiation inducing composition in the S5 stage, and cultured in a shaking incubator for 3 days, and then replaced with S5D4 medium containing the fifth stage differentiation inducing composition, and cultured in a shaking incubator for another 3 days.

[0219] After the S5 stage, the medium was replaced with an S6 medium containing the sixth stage differentiation inducing composition at the S6 stage, and the cells were cultured in a shaking incubator for 2 days.

[0220] The composition of the S1D1 medium is as follows: MCDB 131 (Life Technologies, Cat#10372019) is used as the basic medium, and the following working concentration components are also included: 1% B-27™ supplement (Gibco, Cat#12587-010), 1% Glutamax (Invitrogen, Cat#C11965500CP), 1% double antibody (Gibco, Cat#15140163), 4.5 mM glucose (Sigma, Cat#G7528), 100 ng / ml activin A (Peprotech, Cat#120-14), 0.25 mM sodium ascorbyl phosphate (Sigma, Cat#49752), 6 µM CHIR-99021 (SelleckChem, Cat#S1263), 50 mM PI103 (SelleckChem, Cat#S1038), 10 µM Y-27632 (SelleckChem, Cat# S1049), the concentrations mentioned are all final working concentrations.

[0221] The composition of the S1D2 medium is: MCDB 131 (Life Technologies, Cat#10372019) as the basic medium, and also includes the following working concentration components: 1% Glutamax (Invitrogen, Cat#C11965500CP), 1% double antibody (Gibco, Cat#15140163), 4.5 mM glucose (Sigma, Cat#G7528), 50 ng / mL activin A (Peprotech, Cat#120-14), 0.25 mM sodium vitamin C phosphate (Sigma, Cat#49752), and the above concentrations are all final working concentrations.

[0222] The composition of the S2 medium is as follows: MCDB 131 (Life Technologies, Cat#10372019) is used as the basic medium, and the following working concentration components are also included: 1% double antibody (Gibco, Cat#15140163), 1% Glutamax (Invitrogen, Cat#C11965500CP), 0.5% bovine serum albumin (Sigma, Cat#A4612), 4.5 mM glucose (Sigma, Cat#G7528), 0.25 mM sodium vitamin C phosphate (Sigma, Cat#49752), 5 µM SB431542 (SelleckChem, Cat#S1067), 100 nM WntC59 (SelleckChem, Cat#S7037), 50 ng / ml keratinocyte growth factor (Peprotech, Cat#100-19), and the above concentrations are all final working concentrations.

[0223] The composition of the S3 medium is: DMEM (Gibco, Cat#C11965500CP) as the basic medium, and also includes the following working concentration components: 1% B-27™ additive (Gibco, Cat#12587-010), 1% double antibody (Gibco, Cat#15140163), 0.1µM LDN (SelleckChem, Cat#S7507), 2 µM vitamin A acid (Sigma, Cat#R2625), 0.25 µM Sant-1 (SelleckChem, Cat#S7092), 100 nM WntC59 (SelleckChem, Cat#S7037), and the concentrations are all final working concentrations.

[0224] The composition of the S4D1 medium is as follows: high glucose DMEM (Gibco, Cat#C11965500CP) and B-27™ supplement (Gibco, Cat#12587-010) are mixed in a ratio of 100:1 as the basic medium, and the following working concentration components are also included: 1% double antibody (Gibco, Cat#15140163), 1% Glutamax (Invitrogen, Cat#C11965500CP), 10 mM niacinamide (STEMCELL, Cat#07154), 0.25 mM sodium vitamin C phosphate (Sigma, Cat#49752), 100 ng / mL epidermal growth factor (Peprotech, Cat# AF-100-15), 0.2 µM TPB (Santa Cruz, Cat# SC-204424), 0.25 µM Sant-1 (SelleckChem, Cat#S7092), 10 µM Y-27632 (SelleckChem, Cat#S1049), the concentrations mentioned are the final working concentrations.

[0225] The composition of the S4D2 medium is as follows: high glucose DMEM (Gibco, Cat#C11965500CP) and B-27™ supplement (Gibco, Cat#12587-010) are mixed in a ratio of 100:1 as the basic medium, and the following working concentration components are also included: 1% double antibody (Gibco, Cat#15140163), 1% Glutamax (Invitrogen, Cat#C11965500CP), 10 mM niacinamide (STEMCELL, Cat#07154), 0.25 mM sodium vitamin C phosphate (Sigma, Cat#49752), 100 ng / mL epidermal growth factor (Peprotech, Cat# AF-100-15), 0.25 µM TPB (Santa Cruz, Cat# SC-204424), 0.25 µM Sant-1 (SelleckChem, Cat#S7092), the concentrations mentioned are all final working concentrations.

[0226] The composition of the S5D1 medium is as follows: MCDB 131 is used as the basic medium, and the following working concentration components are also included: 1% B-27™ supplement (Gibco, Cat#12587-010), 1% double antibody (Gibco, Cat#15140163), 1% Glutamax (Invitrogen, Cat#C11965500CP), 0.25 mM sodium vitamin C phosphate (Sigma, Cat#49752), 0.3 μM LDN (SelleckChem, Cat#S7507), 10 μg / mL HS (Sigma, Cat#H3149), 1 μM triiodothyronine (Sigma, Cat#T2877), 0.1 μM γ-secretase inhibitor XX (Calbiochem, Cat#565789), 10 μM ALK5 inhibitor (Selleck, Cat# S7223), 10 μM ISX9 (Selleck, Cat#S7914), 10 uM Y-27632 (SelleckChem, Cat#S1049), 100 nM WntC59 (SelleckChem, Cat#S7037), the concentrations are all final working concentrations.

[0227] The composition of the S5D4 medium is as follows: MCDB 131 is used as the basic medium, and the following working concentration components are also included: 1% B-27™ supplement (Gibco, Cat#12587-010), 1% double antibody (Gibco, Cat#15140163), 1% Glutamax (Invitrogen, Cat#C11965500CP), 50 µg / mL vitamin C phosphate sodium (Sigma, Cat#49752), 0.3 μM LDN (SelleckChem, Cat#S7507), 10 µg / mL HS (Sigma, Cat#H3149), 1 μM triiodothyronine (Sigma, Cat#T2877), 0.1 µM γ-secretase inhibitor XX (Calbiochem, Cat#565789), 10 µM ALK5 inhibitor (Selleck, Cat# S7223), 10 uM Y-27632 (SelleckChem, Cat#S1049), 100 nM WntC59 (SelleckChem, Cat#S7037), the concentrations are all final working concentrations.

[0228] The composition of the S6 medium is: MCDB131 medium (Life Technologies, Cat#10372019), and also includes the following working concentration components: 1% B-27™ supplement (Gibco, Cat#12587-010), 1% double antibody (Gibco, Cat#15140163), 1% Glutamax (Invitrogen, Cat#C11965500CP), 10 µM ALK5 inhibitor (Selleck, Cat# S7223), 10 µg / mL HS (Sigma, Cat#H3149), 1 μM triiodothyronine (Sigma, Cat#T2877), 0.25 mM sodium vitamin C phosphate (Sigma, Cat#49752), 0.5 µM R428 (Selleck, Cat#S2841), 2 mM Acetylcysteine ​​(Sigma, Cat#616-91-1), 10 µM zinc sulfate (Sigma, Cat#7446-19-7).

[0229] After the S1 stage and the S6 stage, the differentiated cells were detected by flow cytometry. Human pluripotent stem cells and cells after the S1 and S6 stages of pancreatic islet induced differentiation were digested into single cells using Accutase, fixed overnight with fixative, washed with washing solution the next day, added with primary antibody for overnight incubation, washed with washing solution, added with secondary antibody for 2 hours, and after the incubation, washed with washing solution before detection. This experiment was detected using flow cytometer BD Calibur and analyzed with FlowJo software.

[0230] like Fig. 20 As shown, SOX17 and FOXA2 are markers of committed endoderm, iPSCs differentiated toward committed endoderm after the S1 stage, and the differentiation efficiency of monoclonal iPSCs after the S1 stage was similar to that of the control group.

[0231] like Fig.21 As shown in the figure, ARX and GCG are markers of α cells, SST and HHEX are markers of δ cells, and NKX6.1 and Cpep are markers of β cells. iPSCs mainly differentiate into pancreatic β cells after the S6 stage, and the differentiation efficiency of monoclonal iPSCs is similar to that of the control group.

[0232] The foregoing detailed description is provided by way of explanation and example, and is not intended to limit the scope of the appended claims. Various changes to the embodiments currently listed in this application are obvious to those of ordinary skill in the art and are retained within the scope of the appended claims and their equivalents.

Claims

1. A method for establishing a monoclonal cell line of pluripotent stem cells, comprising the use of a line establishment medium comprising a ROCK inhibitor, a MEK inhibitor and a GSK3 inhibitor.

2. The method according to claim 1, further comprising the use of CloneR2.

3. The method according to claim 2, further comprising the use of a single cell growth medium, wherein the single cell growth medium comprises the CloneR2.

4. The method according to claim 1, wherein the ROCK inhibitor is Y-27632, the MEK inhibitor is PD0325901, and the GSK3 inhibitor is CHIR-99021. The method according to claim 3 , wherein the culture medium further comprises human heregulin, growth factors and antioxidants.

6. The method according to any one of claims 1 to 5, wherein the pluripotent stem cells are human induced pluripotent stem cells.

7. The method according to any one of claims 1 to 5, comprising culturing the pluripotent stem cells in the establishment medium for 10 to 12 days before obtaining single cells of the pluripotent stem cells.

8. The method according to claim 7, comprising: (1) obtaining a single cell of a pluripotent stem cell from a pluripotent stem cell culture cultured in a lineage establishment medium by a limiting dilution method, wherein the pluripotent stem cell culture is diluted to 5-120 cells / mL; (2) culturing the single cell of the pluripotent stem cell obtained in step (1) in a single cell growth medium for 3-5 days to form a single clone of the pluripotent stem cell; and (3) Cultivating a single clone of the pluripotent stem cells obtained in step (2) in complete culture medium until the end of the lineage establishment.

9. Use of a pluripotent stem cell monoclonal cell line obtained according to the method of any one of claims 1 to 8 in differentiating pancreatic islet cells.

10. A culture medium composition for establishing a monoclonal cell line of pluripotent stem cells, comprising: (1) a cell culture medium, wherein the cell culture medium comprises a ROCK inhibitor, a MEK inhibitor, and a GSK3 inhibitor; (2) A single cell growth medium, wherein the single cell growth medium comprises CloneR2.

Citation Information

Patent Citations

  • Improved reprogramming methods and cell culture platforms

    CN106414721A

  • Culture medium and method for 3D suspension culture of pluripotent stem cells and application of culture medium

    CN118165914A

  • Cellular reprogramming using temporal and transient plasmid vector expression system

    IN202017014771A